LCP2

Across TCGA pan-cancer cohorts, LCP2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated LCP2 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher LCP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LCP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

COAD, HNSC, and LUAD are the cancer types where LCP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	0.911	1.000	.012	36	view →
HNSC	DFS	Tertile	II,III,IV	0.889	1.000	.009	15	view →
LUAD	DFS	Quartile	II,III,IV	0.992	0.878	.022	6	view →
GBM	OS	Tertile	All	0.398	0.619	.032	6	view →
CCRCC	DFS	Quartile	II,III,IV	0.972	0.212	.024	5	view →
PDAC	DFS	Median	II,III,IV	0.621	0.832	.016	5	view →
UCEC	OS	Median	II,III,IV	1.000	0.666	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LCP2–COAD (DFS)

Open the COAD breakdown →